Ultragenyx Pharmaceutical Inc (RARE) - Financial and Strategic SWOT Analysis Review

March 2021 | 58 pages | ID: U0507D37578EN
GlobalData

Abstracts

Ultragenyx Pharmaceutical Inc (RARE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ultragenyx Pharmaceutical Inc (Ultragenyx) develops novel therapeutics for rare and ultra-rare genetic diseases. It has three marketed products, Mepsevii (vestronidase alfa) is approved for the treatment of adults and children with Mucopolysaccharidosis (MPS) VII (Sly syndrome); Dojolvi (triheptanoin), a highly purified, synthetic, 7-carbon fatty acid triglyceride for patients with long-chain fatty acid oxidation disorders (LC-FAOD) and Crysvita (burosumab), a fully human monoclonal antibody for the treatment of X-linked hypophosphatemia (XLH). Its pipeline includes DTX401 for the treatment of patients with glycogen storage disease type Ia, or GSDIa; UX701 for wilson disease; UX053 for glycogen storage disease type III; GTX-102 for the treatment of angelman syndrome in partnership with GeneTx; and DTX301 for the treatment of ornithine transcarbamylase. It works in partnership with various academic institutes and biotechnology companies to advance its product candidates. Ultragenyx is headquartered in Novato, California, the US.

Ultragenyx Pharmaceutical Inc Key Recent Developments

Feb 11,2021: Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
Feb 04,2021: Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2020 Financial Results and Corporate Update
Jan 11,2021: Ultragenyx reports preliminary 2020 revenue and 2021 revenue guidance for Crysvita in Ultragenyx Territories
Jan 08,2021: Ultragenyx announces progress across broad gene therapy portfolio and positive longer-term Data from multiple phase 1/2 gene therapy studies
Nov 09,2020: Ultragenyx announces plans to build large-scale gene therapy manufacturing facility to support pipeline of therapies for rare diseases

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Ultragenyx Pharmaceutical Inc - Key Facts
Ultragenyx Pharmaceutical Inc - Key Employees
Ultragenyx Pharmaceutical Inc - Key Employee Biographies
Ultragenyx Pharmaceutical Inc - Major Products and Services
Ultragenyx Pharmaceutical Inc - History
Ultragenyx Pharmaceutical Inc - Company Statement
Ultragenyx Pharmaceutical Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Ultragenyx Pharmaceutical Inc - Business Description
Product Category: Collaboration and License Revenue
Performance
Product Category: Crysvita
Overview
Performance
Product Category: Dojolvi
Overview
Performance
Product Category: Mepsevii
Overview
Performance
Product Category: Royalty Revenue
Performance
Geographical Segment: All other
Performance
Geographical Segment: Europe
Performance
Geographical Segment: North America
Performance
R&D Overview
Ultragenyx Pharmaceutical Inc - Corporate Strategy
Ultragenyx Pharmaceutical Inc - SWOT Analysis
SWOT Analysis - Overview
Ultragenyx Pharmaceutical Inc - Strengths
Ultragenyx Pharmaceutical Inc - Weaknesses
Ultragenyx Pharmaceutical Inc - Opportunities
Ultragenyx Pharmaceutical Inc - Threats
Ultragenyx Pharmaceutical Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Ultragenyx Pharmaceutical Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 11, 2021: Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
Feb 04, 2021: Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2020 Financial Results and Corporate Update
Jan 11, 2021: Ultragenyx reports preliminary 2020 revenue and 2021 revenue guidance for Crysvita in Ultragenyx Territories
Jan 08, 2021: Ultragenyx announces progress across broad gene therapy portfolio and positive longer-term Data from multiple phase 1/2 gene therapy studies
Nov 09, 2020: Ultragenyx announces plans to build large-scale gene therapy manufacturing facility to support pipeline of therapies for rare diseases
Oct 28, 2020: Ultragenyx announces proposed public offering of common stock
Oct 27, 2020: Ultragenyx reports third quarter 2020 financial results and corporate update
Oct 23, 2020: Ultragenyx and Solid Biosciences announce strategic collaboration to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy
Sep 02, 2020: Ultragenyx appoints Mardi C. Dier as Chief Financial Officer
Sep 01, 2020: Ultragenyx expands leadership team and appoints Ernie Meyer as Chief Human Resources Officer

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Ultragenyx Pharmaceutical Inc, Key Facts
Ultragenyx Pharmaceutical Inc, Key Employees
Ultragenyx Pharmaceutical Inc, Key Employee Biographies
Ultragenyx Pharmaceutical Inc, Major Products and Services
Ultragenyx Pharmaceutical Inc, History
Ultragenyx Pharmaceutical Inc, Subsidiaries
Ultragenyx Pharmaceutical Inc, Key Competitors
Ultragenyx Pharmaceutical Inc, Ratios based on current share price
Ultragenyx Pharmaceutical Inc, Annual Ratios
Ultragenyx Pharmaceutical Inc, Annual Ratios (Cont...1)
Ultragenyx Pharmaceutical Inc, Interim Ratios
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Ultragenyx Pharmaceutical Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Ultragenyx Pharmaceutical Inc, Performance Chart (2016 - 2020)
Ultragenyx Pharmaceutical Inc, Ratio Charts
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021